<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04290663</url>
  </required_header>
  <id_info>
    <org_study_id>2019-002968-27</org_study_id>
    <nct_id>NCT04290663</nct_id>
  </id_info>
  <brief_title>Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up</brief_title>
  <acronym>INTERMEDIATE</acronym>
  <official_title>Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration (3.7 GBq I131 After rhTSH) Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French cancer Institute INCa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is comparing two strategies in intermediate-risk differentiated thyroid cancer
      patients: Systematic radioiodine administration (3.7 GBq I131 after rhTSH) versus decision of
      radioiodine treatment guided by a post-operative work-up based on serum Tg values and
      diagnostic RAI scintigraphy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2020</start_date>
  <completion_date type="Anticipated">February 2028</completion_date>
  <primary_completion_date type="Anticipated">February 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of patients with excellent tumoral response</measure>
    <time_frame>36 months after randomization</time_frame>
    <description>normal neck ultrasonography and Tg/LT4 &lt;0.2 ng/mL and absence of TgAb and if performed, no abnormalities on other imaging modalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's quality-of-life</measure>
    <time_frame>During I131 treatment and at 1 and 3 years</time_frame>
    <description>Comparison of the scores on SF-36 (score between 0 and 100) between 2 arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary, nasal and lachrymal toxicities</measure>
    <time_frame>During I131 treatment and at 1,2,3 and 5 years</time_frame>
    <description>Comparison of the intensity of salivary, nasal and lachrymal toxicities between 2 arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Management cost</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Costs of all medical exams and transportation related to the care within 5 years post-randomization in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's anxiety</measure>
    <time_frame>During I131 treatment and at 1 and 3 years</time_frame>
    <description>Comparison of the scores on STAI questionnaire (score between 20 and 80) between 2 arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">476</enrollment>
  <condition>Thyroid Cancer</condition>
  <condition>Intermediate Risk</condition>
  <arm_group>
    <arm_group_label>RAI group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GUIDED FOLLOW-UP group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systematic RAI-treatment</intervention_name>
    <description>Administration of 3.7 GBq (100 mCi) of I131 after rhTSH-stimulation</description>
    <arm_group_label>RAI group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Decision of RAI-treatment guided by a post-operative assessment</intervention_name>
    <description>The decision-making for the administration of an adapted RAI-treatment will be taken according to the following criteria:
No RAI treatment if Tg/LT4 ≤1 ng/mL and rhTSH-sTg ≤10 ng/mL and normal diagnostic RAI-scintigraphy
1.1 GBq after rhTSH if Tg/LT4&gt;1 ng/mL or rhTSH-sTg&gt;10 ng/mL and normal diagnostic RAI-scintigraphy.
3.7 GBq after rhTSH if metastatic lymph-node(s) detected on diagnostic RAI-scintigraphy without distant metastasis
3.7 GBq after hormone withdrawal if distant metastasis detected on diagnostic RAI-scintigraphy or on the hybrid CT scan of the SPECT-CT acquisition</description>
    <arm_group_label>GUIDED FOLLOW-UP group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subgroup of patients with differentiated thyroid cancer and intermediate-risk defined
             as follows according to TNM 2017:

               -  Papillary thyroid cancer (PTC) without aggressive subtype, follicular thyroid
                  cancer (FTC) (with &lt; 4 foci of vascular invasion) or Hürthle cell carcinoma (HCC)

               -  T1b or T2 with minimal extra-thyroid extension into the perithyroidal soft
                  tissues and/or pN1 with largest nodal dimension between 2 and 10 mm, without
                  extra-capsular invasion and with a number of metastatic nodes ≤ 5

               -  T1aN1 with largest nodal dimension between 2 and 10 mm, without extra-capsular
                  invasion and with a number of metastatic nodes ≤ 5

          -  Patient treated by total thyroidectomy with macroscopically complete tumor resection
             (R0 or R1) ± neck dissection

          -  Total thyroidectomy performed within 6 to 14 10 weeks before randomization

          -  Patient with or without anti-thyroglobulin antibodies (TgAb)

          -  No known distant metastases

          -  Normal post-operative neck ultrasound (US) or if doubtful US, negative cytology and
             normal Tg value (&lt;10 ng/ml) in FNA washout fluid

          -  Post-operative LT4 treatment initiated at least 6 weeks before randomization

          -  Performance Status 0 or 1

          -  Patients aged 18 years or older

          -  Signed informed consent form

          -  Patient who agrees to be followed annually during 5 years

          -  Patient affiliated to the French social security system

        Exclusion Criteria:

          -  • Patients with:

               -  medullary or anaplastic thyroid cancer

               -  or poorly differentiated carcinoma

               -  or well differentiated FTC with at least more than 4 foci of vascular invasion

               -  or PTC with aggressive variants (tall cell or columnar cell carcinoma, diffuse
                  sclerosing papillary, hobnail variant)

               -  NIFTP (Noninvasive follicular thyroid neoplasm with papillary-like nuclear
                  features)

                  • Low-risk or high-risk DTC patients according to ATA 2015, and intermediate-risk
                  patients with extra-thyroid extension into the perithyroidal muscles (pT3b
                  according to pTNM 2017), and/or pN1 with nodal largest dimension &gt;10 mm or with
                  extra-capsular invasion or more than 5 metastatic nodes. This excludes the
                  following patients:

               -  All pT1a, pT3 or pT4

               -  pT1aN0/x with or without minimal extra-thyroid extension

               -  pT1bN0/x, pT2N0/Nx without minimal extra-thyroid extension

               -  pT1aN1 or pT1bN1 or pT2N1 without extra-thyroid extension and with nodal largest
                  dimension &lt;2mm

               -  pT1aN1 or pT1bN1 or pT2N1 without extra-thyroid extension and with nodal largest
                  dimension &gt;10mm

               -  pT2N0/Nx without extra-thyroid extension

               -  pT2N1 without extra-thyroid extension and with nodal largest dimension &lt;2mm

               -  pT2N1 without extra-thyroid extension and with nodal largest dimension &gt;10mm

               -  Surgery considered as macroscopically incomplete (R2)

                    -  Patients who have undergone lobectomy only

                    -  Post-operative neck US with metastatic lymph-nodes confirmed by cytology or
                       by increased Tg (&gt;10 ng/ml) in FNA washout fluid

                    -  Drugs affecting thyroid function including iodinated contrast agents in the
                       6 weeks prior to randomization. Amiodarone should have been stopped at least
                       1 year before randomization.

                    -  Previous RAI treatment for thyroid cancer

                    -  Pregnant or lactating women

                    -  Any associated geographical, social or psychopathological condition that
                       could compromise the patient's ability to participate in the study

                    -  Patient deprived of liberty or placed under the authority of a tutor

                    -  History of malignancy in the past 3 years, except skin cancer excluding
                       melanoma, carcinoma in situ of the cervix. Any other solid tumor or lymphoma
                       (without bone marrow involvement) must have been treated and not have shown
                       signs of recurrence for at least 3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stéphane BARDET, MD</last_name>
    <phone>(33)231455050</phone>
    <email>s.bardet@baclesse.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane BARDET, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radioiodine</keyword>
  <keyword>I131</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

